Somatostatin analog therapy for severe polycystic liver disease: results after 2 years.

ABSTRACT:

Background

We showed in a randomized double-blinded placebo-controlled clinical trial that octreotide long-acting repeatable depot.® (OctLAR(®)) for 12 months reduces kidney and liver growth in autosomal dominant polycystic kidney patients with severe polycystic liver disease (PLD) and liver growth in patients with severe isolated PLD. We have now completed an open-label extension for one additional year to assess safety and clinical benefits of continued use of OctLAR for 2 years (O → O) and examined drug effect in the placebo group who crossed over to OctLAR in Year 2 (P → O).

Methods

The primary end point was change in total liver volume (TLV) measured by magnetic resonance imaging (MRI); secondary end points were changes in total kidney volume (TKV) measured by MRI, glom

SUBMITTER: Hogan MC 

PROVIDER: S-EPMC3433774 | biostudies-literature | 2012 Sep

REPOSITORIES: biostudies-literature